Quantitative Assessment of Saccadic Eye Movements in Progressive Supranuclear Palsy and Idiopathic Parkinson’s Disease
Objective: To investigate whether quantitative assessment of saccadic eye movements can distinguish between patients with progressive supranuclear palsy from patients with idiopathic Parkinson’s disease. Background:…Differentiation of Progressive Supranuclear Paralysis from Multisystem Atrophy and Parkinson’s Disease by Cranial MRI
Objective: To assess differences in cranial MRI between progressive supranuclear palsy (PSP), multisystem atrophy (MSA) and Parkinson's disease (PD) that support the clinical diagnosis. Background:…Development of a Predictive Model for Progressive Supranuclear Palsy Using Real World Data
Objective: To examine diagnoses and symptoms in progressive supranuclear palsy (PSP) patients in the 5 years before PSP diagnosis and to develop a model to…Serum fractalkine levels in Parkinson’s disease: Evidence for neuroinflammation
Objective: Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by loss of dopamine neurons in the substantia nigra. We measured neuroinflammatory marker fractalkine in…Amyotrophic Lateral Sclerosis-Progressive Supranuclear Palsy Phenotype with Negative C9ORF72 Mutation
Objective: We report a rare case of amyotrophic lateral sclerosis (ALS) / progressive supranuclear palsy (PSP) phenotype. Background: Increasing evidence supports a common pathophysiology between…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Quantitative Midbrain Measurement in Diagnosing Variants of Progressive Supranuclear Palsy
Objective: To evaluate the effectiveness of quantitative midbrain measurements in differentiating vPSP from multiple system atrophy (MSA) and Parkinson’s disease (PD). Background: Newly published criteria…Evolution of diagnostic certainty and PSP-predominance types in 187 pathologically confirmed PSP patients
Objective: To examine the evolution of diagnostic certainty and clinical predominance types as defined by the movement disorder society (MDS) criteria for the clinical diagnosis…ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy
Objective: This double-blind, placebo-controlled phase 2 study (M15-562 ARISE study, NCT02985879) assesses the safety and efficacy of ABBV-8E12 treatment in patients with progressive supranuclear palsy…Referral and diagnostic time intervals from symptom onset to death in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Parkinson’s disease (PD)
Objective: To compare referral and diagnostic time intervals from index symptom to death in PSP/CBD and age-sex matched PD. Background: Misdiagnosis and delayed diagnosis are…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 38
- Next Page »